Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $0.02 USD
Change Today -0.0062 / -27.07%
Volume 159.8K
AVXT On Other Exchanges
As of 8:10 PM 10/12/15 All times are local (Market data is delayed by at least 15 minutes).

avax technologies inc (AVXT) Snapshot

Previous Close
Day High
Day Low
52 Week High
04/2/15 - $0.05
52 Week Low
07/23/15 - $0.0031
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield
Current Stock Chart for AVAX TECHNOLOGIES INC (AVXT)

Related News

No related news articles were found.

avax technologies inc (AVXT) Related Businessweek News

No Related Businessweek News Found

avax technologies inc (AVXT) Details

AVAX Technologies, Inc., a development stage biopharmaceutical company, specializes in the development and commercialization of vaccine therapies and other technologies for the treatment of cancer. The company’s autologous cell vaccine immunotherapy products include M-VAX intended for the treatment of melanoma is under phase II clinical trials; and O-VAX intended for the treatment for ovarian cancer is under phase I/II trials. It also provides contract manufacturing and research services. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

9 Employees
Last Reported Date: 05/5/11
Founded in 1990

avax technologies inc (AVXT) Top Compensated Officers

No compensation data is available at this time for the top officers at this company.

Executives, Board Directors

avax technologies inc (AVXT) Key Developments

AVAX Technologies Inc. Announces Expansion of Clinical Study with Autologous Ovarian Cancer Vaccine Ovax

AVAX Technologies Inc. announced that it has expanded its ongoing Phase 1/2 study ("Trial of Autologous, Hapten-Modified Vaccine, OVAX, in Patients with relapsed Stage III or IV Ovarian Cancer") to include all five Cancer Treatment Centers of America(R) (CTCA) regional hospitals. In addition, clinical data from the study was selected to be presented at the Society of Gynecologic Oncology ("SGO") 19(th) Annual Winter Meeting February 20 -- 22, 2014 at Breckenridge, Colorado. The SGO is the premier medical specialty society for health care professionals trained in the comprehensive management of gynecologic cancers.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
AVXT:US $0.02 USD -0.0062

AVXT Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for AVXT.
View Industry Companies

Industry Analysis


Industry Average

Valuation AVXT Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 87.7x
Price/Book NM Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales NM Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact AVAX TECHNOLOGIES INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at